Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has allowed Shire to market Firazyr (icatibant injection) to treat adult patients with acute attacks of hereditary angioedema (HAE).
Subscribe to our email newsletter
Earlier, Shire‘s Firazyr has been granted orphan drug status in the EU and US as a treatment for acute HAE.
Firazyr is supplied in a pre-filled syringe that can be stored at room temperature (up to 77° Fahrenheit), making it portable and accessible for immediate treatment of HAE attacks.
Shire HGT president Sylvie Gregoire said with Firazyr now approved in 38 countries, they are pleased to bring both this novel treatment and their OnePath patient service and support program to US HAE patients.